Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.

Sunil W DuttaMarie L MackEric AliottaKristin A WardDonald A MullerJames M LarnerCamilo E FadulRichard D HallRyan D GentzlerJason P Sheehan

Published in: Journal of neuro-oncology (2020)

Most patients receiving TKIs as part of their initial therapy achieve an early and durable volumetric intracranial response, irrespective of presenting disease burden or neurologic symptoms.

Keyphrases

brain metastases
small cell lung cancer
epidermal growth factor receptor
optic nerve
stem cells
case report
risk factors
physical activity
bone marrow